EUVIMEDEUVIMED entdecken
Crossref

Real-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosus

Feiping Ge, Jiaying He, Miaolan Jiang, Can Cui, Yuchen Wang, Zhangyang Shan, Mengying Zheng, Li Sun, Jianxin Tu

Clinical Rheumatology · 2026-11 · 45 (11) · 6607-6619

DOI: 10.1007/s10067-026-08407-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, online erschienen am 13.09.2026. Verfasst von Feiping Ge und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, 1, Shangcai Village, Nanbaixiang Street, Ouhai District, Wen…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Epstein-Barr Virus Infections. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Medical Science Research Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epstein–Barr virus (EBV) infection has been implicated in systemic lupus erythematosus (SLE), but its clinical relevance in the context of BAFF/APRIL pathway inhibition remains unclear. We evaluated the real-world effectiveness and laboratory-based tolerability of telitacicept in EBV-Reactivated patients with moderate-to-severe SLE.

Methods

In this single-center retrospective cohort study, patients with SLEDAI-2 K > 4 and evidence of EBV infection (EBNA-IgG or VCA-IgG seropositivity, or plasma EBV DNA > 50 IU/mL) received telitacicept or standard-of-care (SOC). Propensity score matching was performed to balance baseline characteristics. The primary outcome was attainment of lupus low disease activity state (LLDAS). Secondary outcomes included time to first LLDAS, cumulative glucocorticoid exposure, and longitudinal laboratory parameters.

Results

A total of 136 patients were included (telitacicept n = 69; SOC n = 67). After matching, 69 telitacicept-treated and 48 SOC-treated patients were analyzed. Overall LLDAS attainment did not differ significantly between groups (37.7% vs 35.4%; P = 0.8). However, telitacicept was associated with a shorter time to first LLDAS ( log-rank P = 0.031) and lower cumulative prednisone-equivalent exposure at endpoint ( P < 0.0001). In exploratory analyses, patients with EBV reactivation achieved LLDAS earlier than those with latent infection (log-rank P = 0.005). In multivariable Cox models, EBV DNA positivity and higher interferon-γ levels were independently associated with earlier LLDAS. No clinically meaningful laboratory abnormalities were observed.

Conclusion

In EBV-infected SLE, telitacicept was associated with earlier disease control and reduced glucocorticoid burden without apparent laboratory tolerability concerns. Prospective studies incorporating longitudinal virological monitoring are needed to confirm these findings. Key Points • EBV infection is common in SLE and may promote B‑cell activation, but treatment outcomes in this subgroup are poorly defined. • This study compared telitacicept versus standard care for effectiveness and laboratory tolerability in EBV‑positive moderate‑to‑severe SLE. • Telitacicept shortened time to LLDAS and reduced cumulative glucocorticoid exposure, despite similar LLDAS attainment rates. • EBV reactivation was associated with earlier disease control; no clinically significant laboratory abnormalities were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicEpstein-Barr Virus InfectionsHumansFemaleAdultRetrospective StudiesMaleHerpesvirus 4, HumanMiddle AgedTreatment OutcomeGlucocorticoidsSeverity of Illness IndexRecombinant Fusion Proteins

Stichwörter der Autor:innen

Biological productsGlucocorticoidsSystemic lupus erythematosusTherapeutics

Substanzen

GlucocorticoidstelitaciceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, 1, Shangcai Village, Nanbaixiang Street, Ouhai District, Wenzhou, Zhejiang, 325000, China.
  • Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, 1, Shangcai Village, Nanbaixiang Street, Ouhai District, Wenzhou, Zhejiang, 325000, China. grassandsun@126.com.
  • Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, 1, Shangcai Village, Nanbaixiang Street, Ouhai District, Wenzhou, Zhejiang, 325000, China. lstujianxin@163.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Medical Science Research Foundation of Zhejiang Province

Zitieren

APA

Ge, F., He, J., Jiang, M., Cui, C., Wang, Y., Shan, Z., Zheng, M., Sun, L., & Tu, J. (2026). Real-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosus. Clinical Rheumatology, 45(11), 6607-6619. https://doi.org/10.1007/s10067-026-08407-1

Vancouver

Ge F, He J, Jiang M, Cui C, Wang Y, Shan Z, et al. Real-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosus. Clinical Rheumatology. 2026;45(11):6607-6619. doi:10.1007/s10067-026-08407-1

BibTeX
@article{Ge2026,
  author = {Ge, Feiping and He, Jiaying and Jiang, Miaolan and Cui, Can and Wang, Yuchen and Shan, Zhangyang and Zheng, Mengying and Sun, Li and Tu, Jianxin},
  title = {Real-world effectiveness of telitacicept in ebv-seropositive patients with systemic lupus erythematosus},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {11},
  pages = {6607--6619},
  doi = {10.1007/s10067-026-08407-1}
}
Kostenlos starten →